Celldex Therapeutics Profile

USD 0.04  1.67%

Payment of 2869 shares by Gerald McMahon of Celldex Therapeutics subject to Rule 16b-3

Celldex Therapeutics Inc insider trading alert for payment of common stock par value $.001 per share by Gerald McMahon, the corporate stakeholder, on February 21, 2018. This event was filed by Celldex Therapeutics Inc with SEC on 2017-07-05. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Celldex Therapeutics Summary

Celldex Therapeutics Inc (CLDX) is traded on NASDAQ in USA. It is located in NEW JERSEY, U.S.A and employs 192 people. Celldex Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 342.81 M. Celldex Therapeutics Inc conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 141.07 M outstanding shares of which 7.89 M shares are currently shorted by private and institutional investors with about 5.82 trading days to cover. CELLDEX THERAPEUT currently holds about 139.43 M in cash with (99.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99.
Check Celldex Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Celldex Therapeutics Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Celldex Therapeutics Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 68% 
Equity ratings for Celldex Therapeutics Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc. Rockefeller University University of Southampton Amgen Inc. Amgen Fremont Seattle Genetics, Inc. Yale University and MedImmune, LLC. Celldex Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ. It employs 192 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameCelldex Therapeutics Inc
President CEO, DirectorAnthony MarucciView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
Business AddressPerryville III Building
CIK Number00744218.0
IndustryPharmaceutical Products
Contact Number908 200 7500
CurrencyUSD - US Dollar

Current Sentiment - CLDX

Celldex Therapeutics Inc Investor Sentiment
Most of Macroaxis users are currently bullish on Celldex Therapeutics Inc. What is your opinion about investing in Celldex Therapeutics Inc? Are you bullish or bearish?
98% Bullish
2% Bearish
Skip  Hide


Celldex Therapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
Celldex Therapeutics Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Celldex Therapeutics Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Celldex Therapeutics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.33March 14, 2017
Celldex Therapeutics Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Celldex Therapeutics Corporate Directors
Keith Brownlie Director
Harry Penner Independent Director
Karen Shoos Independent Director